EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case T-393/23: Action brought on 13 July 2023 — Teva v Commission

ECLI:EU:UNKNOWN:62023TN0393

62023TN0393

July 13, 2023
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

11.9.2023

EN

Official Journal of the European Union

C 321/55

(Case T-393/23)

(2023/C 321/61)

Language of the case: English

Parties

Applicant: Teva GmbH (Ulm, Germany) (represented by: Z. West, S. Love and G. Morgan, lawyers)

Defendant: European Commission

Form of order sought

The applicant claims that the Court should:

declare the applicant’s request for annulment admissible and well- founded;

annul the Contested Decision of 2 May 2023 (published on May 2023) amending the marketing authorisation granted by Decision C(2014)601(final) for ‘Tecfidera — Dimethyl fumarate’, a medicinal product for human use, as well as any later decision, to the extent that they perpetuate and/or replace that decision including any follow-up regulatory actions, in so far as they relate to the applicant;

order the Commission to pay the costs of the proceedings.

Pleas in law and main arguments

In support of the action, the applicant relies on one plea in law alleging that the European Commission failed to observe the simple time limit for meeting the substantive requirement that is necessary to obtain an extension of market protection as required by Article 14(11) of Regulation (EC) No 726/2004 of the European Parliament and of the Council: (1)

An extension of the marketing protection to eleven years may only be granted if an authorisation for a new therapeutic indication is obtained within the first eight years of the marketing authorisation being granted;

Biogen was required to obtain an authorisation for the new indication during the first eight years following the grant of Tecfidera’s marketing authorisation;

The marketing authorisation for Tecfidera was granted on 30 January 2014 and took effect on 3 February 2014. However, the Commission decision to grant an authorisation for the new therapeutic indication was not issued until 13 May 2022 (over three months after the end of the initial eight year period);

Tecfidera therefore should not be granted an additional year of market exclusivity since Biogen failed to meet the statutory requirements of Article 14(11).

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1).

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia